Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke J Laffin

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
Cleveland Clinic Journal of Medicine|August 3, 2021
The obesity paradox in heart failure: What is the role of cardiorespiratory fitness?Asad Khan, Erik H Van Iterson, Luke J Laffin
European Journal of Preventive Cardiology|November 28, 2018
A data-zone scoring system to assess the generalizability of clinical trial results to individual patientsLuke J Laffin, Stephanie A Besser, Francis J Alenghat
The New England Journal of Medicine|March 26, 2026
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. ReplyLuke J Laffin, Stephen J Nicholls, Steven E Nissen
Journal of Hypertension|March 20, 2026
Endothelial triple-pathway vasorelaxation as an adjunctive strategy in resistant hypertensionPaolo Madeddu, Monica Cattaneo, Michael Giuffre, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|May 21, 2014
Overcoming toxicity and side-effects of lipid-lowering therapiesMichael J Wilkinson, Luke J Laffin, Michael H Davidson
American Journal of Hypertension|May 21, 2025
Adherence to Recommended Laboratory Testing for Hypertension: Insights From A Nationwide CohortMaximilian C Volk, Ahmad Safdar, Omer Ashruf, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|June 5, 2016
Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot StudyLuke J Laffin, Colleen Majewski, Chuanhong Liao, et al.
Current Atherosclerosis Reports|August 16, 2024
Obicetrapib-the Rebirth of CETP Inhibitors?Bliss Chang, Luke J Laffin, Ashish Sarraju, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|September 23, 2020
Prevalence and clinical outcomes of patients with apparent treatment-resistant hypertension enrolled in Phase 2 cardiac rehabilitationLuke J Laffin, Asad Khan, Katherine Lang, et al.
The Canadian Journal of Cardiology|May 2, 2026
Venous thromboembolism risk among different statins: a retrospective cohort studyBernardo F Spiazzi, Carolina P Zingano, Akiva Rosenzveig, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Cleveland Clinic Journal of Medicine|August 3, 2021
The obesity paradox in heart failure: What is the role of cardiorespiratory fitness?Asad Khan, Erik H Van Iterson, Luke J Laffin
European Journal of Preventive Cardiology|November 28, 2018
A data-zone scoring system to assess the generalizability of clinical trial results to individual patientsLuke J Laffin, Stephanie A Besser, Francis J Alenghat
The New England Journal of Medicine|March 26, 2026
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. ReplyLuke J Laffin, Stephen J Nicholls, Steven E Nissen
Journal of Hypertension|March 20, 2026
Endothelial triple-pathway vasorelaxation as an adjunctive strategy in resistant hypertensionPaolo Madeddu, Monica Cattaneo, Michael Giuffre, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|May 21, 2014
Overcoming toxicity and side-effects of lipid-lowering therapiesMichael J Wilkinson, Luke J Laffin, Michael H Davidson
American Journal of Hypertension|May 21, 2025
Adherence to Recommended Laboratory Testing for Hypertension: Insights From A Nationwide CohortMaximilian C Volk, Ahmad Safdar, Omer Ashruf, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|June 5, 2016
Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot StudyLuke J Laffin, Colleen Majewski, Chuanhong Liao, et al.
Current Atherosclerosis Reports|August 16, 2024
Obicetrapib-the Rebirth of CETP Inhibitors?Bliss Chang, Luke J Laffin, Ashish Sarraju, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|September 23, 2020
Prevalence and clinical outcomes of patients with apparent treatment-resistant hypertension enrolled in Phase 2 cardiac rehabilitationLuke J Laffin, Asad Khan, Katherine Lang, et al.
The Canadian Journal of Cardiology|May 2, 2026
Venous thromboembolism risk among different statins: a retrospective cohort studyBernardo F Spiazzi, Carolina P Zingano, Akiva Rosenzveig, et al.
Pageof 9